Based on the potential role of ASK1 in hepatic injury, inflammation, and fibrosis as determined by animal models, recently the safety and efficacy of selonsertib as a selective ASK1 inhibitor were evaluated in patients with NASH and stage 2 or 3 fibrosis. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.